Accepted Manuscript

Systematic Review and Meta-Analysis: Early Treatment Responses of Selective-Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder

Anjali L. Varigonda, MD, Ewgeni Jakubovski, BA, Michael H. Bloch, MD, MS

PII: S0890-8567(16)31160-1

DOI: 10.1016/j.jaac.2016.07.768

Reference: JAAC 1593

To appear in: Journal of the American Academy of Child & Adolescent

Psychiatry


Received Date: 1 February 2016

Revised Date: 30 April 2016

Accepted Date: 4 July 2016

Please cite this article as: Varigonda AL, Jakubovski E, Bloch MH, Systematic Review and Meta-Analysis: Early Treatment Responses of Selective-Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder, *Journal of the American Academy of Child & Adolescent Psychiatry* (2016), doi: 10.1016/j.jaac.2016.07.768.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Systematic Review and Meta-Analysis: Early Treatment Responses of Selective-Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder RH = Systematic Review and Meta-Analysis

Anjali L. Varigonda MD, Ewgeni Jakubovski BA, Michael H. Bloch, MD, MS Supplemental material cited in this article is available online.

Accepted July 28, 2016

This article was reviewed under and accepted by deputy editor John T. Walkup, MD.

Dr. Varigonda is with the University of Vermont Medical Center, Burlington. Mr. Jakubovski is with the Yale Child Study Center, New Haven, CT. Dr. Bloch is with the Yale Child Study Center and Yale University.

Dr. Bloch gratefully acknowledges support from the National Institutes of Health (NIH; K23MH091240 and R25MH077823) and from the National Center for Research Resources (UL1 RR024139), a component of NIH, and NIH roadmap for Medical Research. Dr. Bloch also acknowledges support from the National Alliance for Research on Schizophrenia and Depression, the Patterson Foundation, and the Tourette Association of America.

Mr. Jakubovski served as the statistical expert for this research.

The authors would like to thank the Klingenstein Third Generation Foundation for their funding of medical student fellowship programs in child psychiatry at Yale University and Vermont that helped foster the authors' initial meeting and collaboration.

Disclosure: Dr. Bloch has received grant or research support from the National Institutes of Health, the Tourette Association of America, NARSAD, and the Patterson Foundation. He has served as a consultant to Therapix Biosciences and Biohaven Pharmaceuticals. Dr. Varigonda and Mr. Jakubovski report no biomedical financial interests or potential conflicts of interest. Correspondence to Michael H. Bloch, MD, MS, Child Study Center, Yale University School of Medicine, PO Box 2070900, New Haven, CT 06520; email: michael.bloch@yale.edu.

Download English Version:

https://daneshyari.com/en/article/4931616

Download Persian Version:

https://daneshyari.com/article/4931616

<u>Daneshyari.com</u>